1622P A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
| Autor: | Aggarwal, R., Tagawa, S.T., Monk, P., Zhu, X., Jones, R.J., Linch, M., Costin, D., de Bono, J.S., Karsh, L.I., Petrylak, D.P., Borderies, P., Deshpande, R., O'Neill, V., Zhang, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S979-S979 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|